Core Viewpoint - VEON Ltd. is enhancing its market position through strategic moves in Pakistan, particularly with its subsidiary Jazz, which has secured significant mobile spectrum to improve digital services and infrastructure [2][3][6] Financial Performance - VEON is expected to report quarterly earnings on March 13, 2026, with an estimated earnings per share (EPS) of $1.33 and projected revenue of approximately $1.12 billion [2][6] - The company has a price-to-earnings (P/E) ratio of 4.80, indicating a low valuation relative to its earnings [4][6] - VEON's price-to-sales ratio is 0.73, suggesting a modest market valuation of its sales [4][6] - The enterprise value to sales ratio is 1.56, reflecting the company's total valuation in relation to its revenue [4] Debt and Earnings Metrics - VEON has a debt-to-equity ratio of 3.72, indicating a higher level of debt compared to equity [5][6] - The company maintains a strong earnings yield of 20.82%, providing substantial returns on its earnings [5][6] - The current ratio of 0.95 suggests that VEON has slightly less than enough current assets to cover its current liabilities, emphasizing the need for effective cash flow management [5] Strategic Developments - Jazz's acquisition of 190 MHz across various bands is expected to support faster broadband and next-generation digital services, aligning with VEON's growth strategy [3][6] - The mobile spectrum auction in Pakistan, which Jazz won, nearly tripled the spectrum available to mobile operators, significantly enhancing the country's digital infrastructure [2][3]

Core Insights - Petco Health & Wellness Co. Inc. is a significant player in the pet care industry, providing a variety of products and services through retail stores and an online platform [1] - The company reported fourth-quarter revenue of $1.51 billion, slightly exceeding consensus estimates, but incurred a quarterly loss of 1 cent per share, missing analysts' expectations for a profit of 2 cents [3][6] - CEO Joel Anderson highlighted strategic progress, focusing on strengthening the leadership team and rebuilding the economic model to drive sustainable, profitable growth [4] Stock Performance - Petco's stock is currently trading at $3.23, reflecting a notable increase of 34.58% with a rise of $0.83 [5][6] - The stock has fluctuated between a low of $2.91 and a high of $3.34 during the day, with a market capitalization of approximately $908.28 million [5][6] - Over the past year, the stock reached a high of $4.51 and a low of $2.24 [5] Analyst Outlook - Chris Bottiglieri from BNP Paribas set a price target of $2.18 for Petco, indicating a potential downside of approximately -33.54% from the current trading price [2][6]

Core Viewpoint - Bit Digital Inc is positioned for potential growth due to its strategic investments in Ethereum and related assets, with analysts projecting a significant upside in its stock price [2]. Financial Projections - The company is expected to report an earnings per share (EPS) of -$0.02 and revenue of approximately $31.7 million for the upcoming quarterly earnings on March 13, 2026 [1][6]. Investment Ratings - Noble Capital Markets has reaffirmed an 'Outperform' rating for Bit Digital, setting a price target of $5.50, indicating substantial upside from the current trading price of $1.60 [2][6]. Ethereum Holdings - As of February 28, 2026, Bit Digital holds approximately 155,434 ETH, valued at around $305.4 million, with an annualized yield of about 2.7% from staking 89% of its Ethereum [3][6]. Valuation Metrics - The company's financial metrics indicate a low valuation, with a price-to-earnings (P/E) ratio of approximately 3.74, a price-to-sales ratio of around 3.22, and an enterprise value to sales ratio of 2.37 [4]. Financial Health - Bit Digital maintains a strong financial position, characterized by a low debt-to-equity ratio of 0.046 and a robust current ratio of 17.53, indicating excellent short-term financial health and liquidity [5].

Core Insights - Viking Therapeutics is a biotech company focused on innovative treatments for metabolic and endocrine disorders, particularly advancing its VK2735 program, a dual GLP-1/GIP agonist for obesity and diabetes [1] Stock Performance - Jefferies reiterated a "Buy" rating for VKTX on March 12, 2026, with the stock priced at $35.49, following a 16.5% rise in February after the release of the fourth-quarter earnings [2] - The current stock price of VKTX is $35.36, reflecting a decrease of approximately 1.13%, with a market capitalization of around $4.09 billion [4] - Over the past year, VKTX has fluctuated between a high of $43.15 and a low of $18.92, indicating significant volatility in its stock performance [4] Drug Development Focus - The VK2735 program, especially its oral formulation, is a key focus for investors, despite previous market disappointments with top-line results [3] - Viking Therapeutics is conducting two Phase 3 trials for the subcutaneous formulation of VK2735, with a maintenance study planned for 2026 to assess the tolerability of the oral formulation [3]

Core Insights - Granite Ridge Resources, Inc. (NYSE: GRNT) is focused on the Permian Basin and has shown proactive management of resources and growth prospects [1] - The company is experiencing a cash burn of $71 million in 2026 due to increased lease operating expenses while hedging 60% of its oil production to mitigate price volatility [2][6] - Despite a net loss of $25.1 million in 2025, Granite Ridge achieved an adjusted EBITDAX of $69.5 million and aims to generate free cash flow by 2027 [3][4][6] Financial Performance - In 2025, Granite Ridge reported a 27% increase in total production, reaching 35,120 barrels of oil equivalent per day [3] - The company declared a dividend of $0.11 per share and maintained total liquidity of $339.5 million, with a net debt to adjusted EBITDAX ratio of 1.2x [4] - As of the latest data, GRNT's stock price is $5.23, with a market capitalization of approximately $686 million, reflecting a 3.06% increase [5] Strategic Moves - Director Everard Michele J purchased 5,000 shares at $5.17 each, indicating confidence in the company's future [1][6] - The company plans to increase its hedging of oil production to 75%-80% in the second quarter of 2026 [2]

Core Viewpoint - Exane BNP Paribas maintains a Neutral rating for Dollar General, advising investors to hold the stock priced at $136.43, despite some positive financial performance and a negative market reaction to its future outlook [1][6] Financial Performance - Dollar General's shares fell approximately 7% following the release of its fourth-quarter earnings, despite reporting earnings of $1.93 per share, which exceeded the analyst estimate of $1.65 [2] - The company also surpassed sales expectations with $10.91 billion in revenue compared to the anticipated $10.82 billion, indicating strong performance in the last quarter [2][4] Fiscal Guidance - The fiscal 2026 guidance provided by Dollar General was less optimistic, forecasting GAAP earnings per share between $7.10 and $7.35, slightly below market estimates of $7.23 [3][6] - Sales for fiscal 2026 are expected to range from $44.30 billion to $44.5 billion, reflecting a cautious outlook [3] Operational Efficiency - In the fourth quarter, Dollar General experienced a 5.9% increase in net sales, driven by a 4.3% rise in same-store sales [4] - Operating profit more than doubled to $606.3 million, and diluted earnings per share surged by 121.8% compared to the previous year, showcasing strong operational efficiency [4] Market Context - The broader market faced challenges, with declines in the Dow Jones, NASDAQ, and S&P 500, while Dollar General's sector showed resilience with utilities shares rising by 0.8% [5] - The company's modest outlook for fiscal 2026 remains a concern for investors, impacting its stock performance [5]

Core Insights - Gambling.com Group Limited (NASDAQ:GAMB) reported strong Q4 2025 earnings with an EPS of $0.30, exceeding the estimated $0.17 [1][6] - The company achieved revenue of $46.24 million, slightly below the estimate of $46.51 million, but still representing a 31% year-over-year increase [2][6] - Adjusted EBITDA increased by 5% to $15.5 million, indicating effective operational management [2][6] Revenue Breakdown - GAMB's sports data services experienced a 29% quarter-on-quarter growth, contributing 26% to total revenue, marking its highest contribution to date [3] - The marketing segment also performed well, further enhancing the company's financial success [3] Financial Metrics - The company has a P/E ratio of 81.26, reflecting investor confidence in future earnings potential [4] - A price-to-sales ratio of 1 indicates that the market values the company at a level equal to its sales [4] - The enterprise value to sales ratio stands at 1.52, while the enterprise value to operating cash flow ratio is 5.64, providing insights into the company's valuation [4] Debt and Liquidity - GAMB's debt-to-equity ratio is 0.66, indicating moderate use of debt financing [5] - The current ratio of 0.46 suggests potential challenges in meeting short-term liabilities [5] - The earnings yield of 1.23% demonstrates the company's ability to generate earnings for investors [5]

Core Insights - Indivior Pharmaceuticals is a key player in long-acting injectable treatments for opioid use disorder (OUD), focusing on evidence-based solutions like SUBLOCADE, which is a monthly injectable form of buprenorphine aimed at improving patient outcomes and reducing healthcare costs [1] - A recent study indicates that patients adhering to SUBLOCADE for 12 months experienced a 42% reduction in non-MOUD medical costs, supporting the company's strategy to evaluate OUD treatment based on total healthcare costs [1] Financial Performance - Indivior's stock (INDV) has a price-to-earnings (P/E) ratio of 18, reflecting investor confidence in its earnings potential [2] - The company faces financial challenges, indicated by a negative enterprise value to operating cash flow ratio of -207.20 and a debt-to-equity ratio of -3.58, suggesting potential difficulties in cash flow generation and financial structuring [2] - The current ratio of 0.71 indicates that Indivior may struggle to cover short-term liabilities with its short-term assets [3] Industry Position - Despite financial challenges, Indivior's focus on long-acting injectable treatments and evidence-based care positions it as a leader in addressing OUD, which is recognized as a chronic but treatable brain disease [3]

Shares of Ulta Beauty slid after hours on Thursday after the cosmetics retailer forecast a profit and same-store sales for this year that were below Wall Street's estimates, adding that it expects mor... ...

Arbor Realty Trust, Inc. ( ABR ) has been suffering some portfolio setbacks, manifested in higher delinquencies, loan extensions, and modifications. The company is still profitable, and given its current valuation, I am Bashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bach ...